Medizinische Klinik III, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
Roche Diagnostics, Basel, Switzerland.
Eur Heart J. 2017 Nov 1;38(41):3049-3055. doi: 10.1093/eurheartj/ehx492.
The diagnostic evaluation of acute chest pain has been augmented in recent years by advances in the sensitivity and precision of cardiac troponin assays, new biomarkers, improvements in imaging modalities, and release of new clinical decision algorithms. This progress has enabled physicians to diagnose or rule-out acute myocardial infarction earlier after the initial patient presentation, usually in emergency department settings, which may facilitate prompt initiation of evidence-based treatments, investigation of alternative diagnoses for chest pain, or discharge, and permit better utilization of healthcare resources. A non-trivial proportion of patients fall in an indeterminate category according to rule-out algorithms, and minimal evidence-based guidance exists for the optimal evaluation, monitoring, and treatment of these patients. The Cardiovascular Round Table of the ESC proposes approaches for the optimal application of early strategies in clinical practice to improve patient care following the review of recent advances in the early diagnosis of acute coronary syndrome. The following specific 'indeterminate' patient categories were considered: (i) patients with symptoms and high-sensitivity cardiac troponin <99th percentile; (ii) patients with symptoms and high-sensitivity troponin <99th percentile but above the limit of detection; (iii) patients with symptoms and high-sensitivity troponin >99th percentile but without dynamic change; and (iv) patients with symptoms and high-sensitivity troponin >99th percentile and dynamic change but without coronary plaque rupture/erosion/dissection. Definitive evidence is currently lacking to manage these patients whose early diagnosis is 'indeterminate' and these areas of uncertainty should be assigned a high priority for research.
近年来,由于心脏肌钙蛋白检测的灵敏度和精确度的提高、新的生物标志物的出现、成像方式的改进以及新的临床决策算法的发布,急性胸痛的诊断评估得到了增强。这一进展使医生能够在初始患者就诊后更早地诊断或排除急性心肌梗死,通常是在急诊科环境中,这可能有助于及时启动基于证据的治疗、为胸痛寻找替代诊断或出院,并更好地利用医疗资源。根据排除算法,相当一部分患者属于不确定类别,对于这些患者的最佳评估、监测和治疗,几乎没有基于证据的指导。ESC 心血管圆桌会议提出了在临床实践中优化早期策略应用的方法,以改善急性冠状动脉综合征早期诊断方面的患者护理。以下是考虑的特定“不确定”患者类别:(i)有症状和高敏肌钙蛋白<第 99 百分位数的患者;(ii)有症状和高敏肌钙蛋白<第 99 百分位数但高于检测限的患者;(iii)有症状和高敏肌钙蛋白>第 99 百分位数但无动态变化的患者;(iv)有症状和高敏肌钙蛋白>第 99 百分位数且有动态变化但无冠状动脉斑块破裂/侵蚀/夹层的患者。目前,尚无明确证据可用于管理这些早期诊断“不确定”的患者,这些不确定领域应被高度优先考虑进行研究。